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“Centralized” (ancestral and consensus) HIV-1 envelope immunogens induce broadly cross-reactive T cell responses in laboratory animals;
however, their potential to elicit cross-reactive neutralizing antibodies has not been fully explored. Here, we report the construction of a panel of
consensus subtype B (ConB) envelopes and compare their biologic, antigenic, and immunogenic properties to those of two wild-type Env controls
from individuals with early and acute HIV-1 infection. Glycoprotein expressed from full-length (gp160), uncleaved (gp160-UNC), truncated (gp145),
and N-linked glycosylation site deleted (gp160-201N/S) versions of the ConB env gene were packaged into virions and, except for the fusion
defective gp160-UNC, mediated infection via the CCR5 co-receptor. Pseudovirions containing ConB Envs were sensitive to neutralization by patient
plasma andmonoclonal antibodies, indicating the preservation of neutralizing epitopes found in contemporary subtype B viruses.When used as DNA
vaccines in guinea pigs, ConB and wild-type env immunogens induced appreciable binding, but overall only low level neutralizing antibodies.
However, all four ConB immunogens were significantly more potent than one wild-type vaccine at eliciting neutralizing antibodies against a panel of
tier 1 and tier 2 viruses, and ConB gp145 and gp160 were significantly more potent than both wild-type vaccines at inducing neutralizing antibodies
against tier 1 viruses. Thus, consensus subtype B env immunogens appear to be at least as good as, and in some instances better than, wild-type B env
immunogens at inducing a neutralizing antibody response, and are amenable to further improvement by specific gene modifications.
© 2006 Elsevier Inc. All rights reserved.Keywords: HIV-1 genetic variation; Centralized HIV-1 immunogens; HIV-1 envelope glycoprotein; Subtype BIntroduction
Genetic variation is a hallmark of human immunodeficiency
virus type 1 (HIV-1) infection and a major obstacle to AIDS
vaccine development (Korber et al., 2001; Mullins and Jensen,⁎ Corresponding author. Department of Medicine, University of Alabama at
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doi:10.1016/j.virol.2006.10.0172006; Worobey, in press). Since its introduction into the human
population almost a century ago (Korber et al., 2000; Sharp et
al., 2000), pandemic HIV-1 (HIV-1 group M) has continued to
diversify and today comprises a spectrum of viral variants of
unprecedented genetic complexity. Viruses belonging to this
“main” group of HIV-1 have been classified into “subtypes” and
“circulating recombinant forms” (CRFs) based on their
phylogenetic relationships (Leitner et al., 2005). Subtypes
represent major clades that resulted from the expansion of
founder viruses early in the group M epidemic (Vidal et al.,
219D.L. Kothe et al. / Virology 360 (2007) 218–2342000; Rambaut et al., 2001; Worobey, in press); CRFs represent
descendants of complex recombinants of two or more group M
subtypes (Robertson et al., 1995; Leitner et al., 2005). Among
all known subtypes and CRFs, subtype C is the most prevalent,
accounting for more than 50% of group M infections worldwide
and representing the predominant HIV-1 lineage in southern
Africa, China, and India (Osmanov et al., 2002). Subtype A and
related CRFs account for roughly 30% of group M infections,
and are primarily found in west and central Africa. Subtype B
comprises about 15% of group M infections and is the
predominant subtype in Europe, Australia, and the Americas
(subtype B and related recombinants are also common in Asia).
Since all other subtypes and CRFs are less prevalent (Osmanov
et al., 2002), candidate vaccines have historically been selected
from members of subtypes A, B, and C (Douek et al., 2006;
IAVI, 2006; HVTN, 2006). However, with envelope protein
sequence distances as high as 38%, selecting a single
contemporary virus as a vaccine strain is unlikely to provide
sufficient global, or even regional, coverage of HIV-1 diversity.
An inherent problem associated with selecting a contempor-
ary HIV-1 strain as a candidate immunogen is that this virus is
as distant from other contemporary viruses as these are from
each other. To reduce this distance, we and others have
proposed the use of “centralized” HIV-1 immunogens,
expressed from consensus or reconstructed ancestor gene
sequences (Korber et al., 2001; Gaschen et al., 2002;
Ellenberger et al., 2002; Mullins et al., 2004; Nickle et al.,
2003; Novitsky et al., 2002). Because of their “central” position
within an evolutionary tree, these inferred sequences are almost
half as distant from contemporary HIV-1 strains as the latter are
from each other and should thus contain a greater number of
conserved epitopes. However, since centralized sequences
encode artificial gene products, their antigenicity and immuno-
genicity cannot be predicted. Moreover, their biological
properties may vary since their exact sequence depends on the
input data, the alignment, and the particular algorithm used for
reconstruction. For example, ancestral sequences which repre-
sent an attempt to reconstruct the common ancestor of a given
viral lineage, tend to be artificially enriched for certain
nucleotides, may include recently fixed escape mutations, and
are vulnerable to sampling bias (Gaschen et al., 2002).
Consensus sequences which represent the most common
amino acid residue at any one position in a protein alignment
are also vulnerable to sampling bias and may bring together
polymorphisms not linked in natural infections (Doria-Rose et
al., 2005). Finally, genomic regions that evolve by frequent
insertions and deletions, like the variable loop regions in the
envelope glycoprotein, have to be reconstructed manually,
using conserved elements (e.g., glycosylation sites) spanning
these regions as a guide. Thus, centralized sequences represent
only imperfect approximations of HIV-1's evolutionary history
and require extensive experimental validation to ensure that
they represent suitable immunogens.
To date, five centralized Env immunogens, derived from M
group (Con6, ConS) and subtype specific consensus (ConC)
and ancestral (An1-EnvB, AncC) env genes, have been
generated and tested as DNA and/or protein vaccines (Doria-Rose et al., 2005; Gao et al., 2005; Weaver et al., 2006; Kothe et
al., 2006; Liao et al., 2006). All of these genes expressed
functional Env glycoproteins and elicited humoral and/or
cellular immune responses in small animal models (Doria-
Rose et al., 2005; Gao et al., 2005; Weaver et al., 2006; Kothe et
al., 2006; Liao et al., 2006). However, only the group M specific
ConS Env immunogen (delivered as an oligomeric gp140
protein) elicited high titer antibodies that neutralized primary
isolates from three different group M clades (Liao et al., 2006).
The other four immunogens elicited either no or only negligible
neutralizing antibody responses. Interestingly, the ConS vaccine
used expressed a secreted Env glycoprotein that lacked the
gp120/gp41 cleavage site (C), the fusion peptide (F), and an
immunodominant (I) region in the transmembrane gp41 domain
(ConSΔCFIgp140). The improved immunogenicity of the
ConS Env protein may thus be due, at least in part, to these
gene modifications (Chakrabarti et al., 2002), although its
ability to induce cross-clade responses is likely a consequence
of its central nature.
To examine directly whether centralized env immunogens
can be improved by targeted gene modifications, we con-
structed a panel of consensus subtype B (ConB) env genes that
expressed glycoproteins with changes in functional domains
previously shown to influence antigenic and/or immunogenic
properties of wild-type Env proteins (Edwards et al., 2002,
Barnett et al., 2001; Bower et al., 2004; Grundner et al., 2005;
Yang et al., 2001; Hu et al., 2005). The rationale for generating
such a panel was several-fold. First, subtype B is the most
extensively studied group M subtype (Leitner et al., 2005), and
thus an obvious target for immunogen design. Second, despite a
growing number of centralized gene products, consensus
subtype B env immunogens have not yet been reported.
Third, a subtype B env ancestor vaccine elicited only weak
neutralizing antibody responses in laboratory animals (Doria-
Rose et al., 2005). Finally, a formal comparison of consensus
and wild-type subtype B env vaccines has not been conducted.
Here, we describe the antigenic properties of native and
modified ConB Env proteins and compare the immunogenicity
of ConB env DNA vaccines to those of two contemporary
(wild-type) env controls.
Results
Design of native and modified consensus subtype B (ConB) env
genes
The ConB Env sequence was generated by selecting the most
common amino acid at each position of a full-length Env
protein alignment derived from 137 subtype B viruses deposited
in the 2001 HIV Sequence Database (Gaschen et al., 2002;
Kothe et al., 2006). Hypervariable loop regions were recon-
structed as described (Gaschen et al., 2002; Kothe et al., 2006).
Fig. 1A depicts an alignment of ConB gp160 and the deduced
protein sequences of two contemporary wild-type env controls
derived from patients during the acute (WITO4160.27) and
early (CAAN5342.A2) phase of HIV-1 infection (Li et al.,
2005). Of note, ConB Env is considerably shorter (850 amino
Fig. 1. Generation of consensus subtype B (ConB) envelopes. (A) Alignment of the deduced protein sequence of full-length (unmodified) ConB Env with those of
recently transmitted, contemporary subtype B Env controls (CAAN5342.A2, WITO4160.27). Sequences are compared to ConB gp160, with dots indicating sequence
identity, and dashes indicating gaps introduced for optimal alignment. Potential N-linked glycosylation sites are highlighted in red. The locations of signal peptide (SP)
and gp120/gp41 cleavage sites are indicated, as are the positions of the variable loops (V1–V5) and the transmembrane (TM) domain. (B) Location of specific
mutations within the ConB Env sequence. Amino acid substitutions are highlighted (see text for design and construction details of ConB gp160-201N/S, ConB gp160-
UNC, and ConB gp145).
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Fig. 2. Processing and virion incorporation of ConB Envs. Consensus (ConB
gp160, ConB gp160-UNC, ConB gp145, and ConB gp160-201N/S) and wild-
type (CAAN5342.A2 and WITO41260.27) env genes were co-transfected with
the HIV-1/SG3Δenv backbone vector. Purified particles were examined by
Western blot analysis using antibodies specific for HIV-1 Env (polyclonal anti-
gp120; upper panel) and Gag (monoclonal anti-p24; lower panel) proteins (the
SG3Δenv backbone vector was included for control). The positions of the
uncleaved gp160 precursor, the mature gp120 protein, and the p24 Gag protein
are indicated.
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lation sites in gp120) than a previously reported subtype B Env
ancestor (884 amino acids; 30 N-linked glycosylation sites in
gp120) (Doria-Rose et al., 2005); this is because we opted to
create hypervariable regions that contain a minimum number of
residues, reasoning that shorter loops might give better
accessibility to neutralizing epitopes.
To investigate whether synthetic Env proteins could be
modified to improve their immunogenicity, we generated three
ConB variants. Cleavage site mutations can alter the
antigenicity of wild-type Env proteins (Schulke et al., 2002;
Si et al., 2003; Herrera et al., 2005; Pancera and Wyatt, 2005)
and are thought to be responsible (at least in part) for the
improved immunogenicity of soluble gp140 oligomers
compared to monomeric gp120 (Barnett et al., 2001; Bower
et al., 2004; Grundner et al., 2005; VanCott et al., 1997; Yang
et al., 2001). We thus generated a fusion-defective version of
ConB (ConB gp160-UNC) by replacing two amino acid
residues in the gp120/gp41 cleavage site (REKR→SEKS).
Truncations of the gp41 cytoplasmic domain have also been
reported to influence the conformation of the gp120 surface
subunit and to expose conserved neutralizing determinants in
some wild-type Env proteins (Edwards et al., 2002). We
therefore introduced a stop codon immediately following the
membrane-spanning domain to generate a truncated, yet still
anchored, version of ConB Env (ConB gp145). Finally, in
wild-type subtype B viruses, the V1V2 loop is believed to
occlude the CCR5 binding site, but the position of this loop
can be altered by removal or repositioning of a N-linked
glycosylation site at its base (Kolchinsky et al., 2001a,b). To
examine whether the removal of an analogous glycosylation
site would expose ConB neutralization epitopes that are
normally masked by the V1V2 loop, we replaced an
asparagine residue at position 201 with a serine residue,
generating ConB gp160-201N/S. Fig. 1B depicts a schematic
representation of these modifications.
Functional analysis of ConB Env glycoproteins
Codon-usage optimization of HIV/SIV gene sequences
enhances protein expression in vitro (Haas et al., 1996; Andre
et al., 1998; Gao et al., 2003; Kothe et al., 2006) and increases
humoral and cellular immune responses to DNA vaccines in
laboratory animals in vivo (Robinson and Torres, 1997; Torres
et al., 1997; Letvin et al., 2004; Mascola et al., 2005; Rao et al.,
2006). To generate constructs suitable for DNAvaccination, we
synthesized codon-usage optimized ConB, CAAN5342.A2,
and WITO4160.27 env genes using an algorithm first described
by Seed and colleagues (Haas et al., 1996; Andre et al., 1998).
All env gene modifications were introduced into the codon-
usage optimized sequence of ConB. The integrity of the newly
derived constructs was tested following transfection into 293T
cells. Consistent with previous reports (Doria-Rose et al., 2005;
Gao et al., 2005; Kothe et al., 2006; Liao et al., 2006),
consensus and codon optimized wild-type env genes expressed
high levels of Env glycoprotein. Moreover, all constructs
expressed the same amounts of Env glycoprotein as determinedby Western blot analysis of transfected cell lysates (data not
shown).
To determine whether the ConB-derived envelope glycopro-
teins were packaged into HIV-1 particles, expression plasmids
were co-transfected with an env-deficient HIV-1 (SG3Δenv)
backbone vector. Optimized CAAN5342.A2 andWITO4160.27
env constructs, as well as the env-minus backbone vector alone,
were included as controls. Culture supernatants were harvested,
centrifuged through a 20% sucrose cushion, normalized by p24
Gag content, and examined by Western Blot analysis using
antibodies specific for HIV-1 Gag (p24) and Env (gp120)
proteins. As shown in Fig. 2, the ConB-derived Envs
incorporated efficiently into virus particles, although most of
the virion-associated glycoprotein was only incompletely
processed. Cleaved gp120 was detectable in all preparations,
except for the cleavage defective ConB gp160-UNC protein.
However, based onWestern blot intensities, the relative amounts
of gp120 were lower than those of the corresponding precursors
(Fig. 2). Importantly, incomplete processing was not only
observed for the synthetic ConB Envs, but also for the
contemporary CAAN5342.A2 and WITO4160.27 Envs, sug-
gesting saturation of furin and other cellular proteases involved
in gp160 processing in 293T cells over-expressing Env proteins
(Binley et al., 2002; Gao et al., 2003; Kothe et al., 2006).
To determine whether the particle-associated ConB envelope
glycoproteins were capable of mediating fusion and entry into
appropriate target cells, purified pseudovirion preparations were
analyzed in a single round infectivity assay (Derdeyn et al.,
2000; Platt et al., 1998; Wei et al., 2002). JC53-BL cells express
high levels of CD4, CCR5, and CXCR4 receptor molecules and
are stably transfected with β-galactosidase and luciferase
reporter genes under the control of the HIV-1 long terminal
repeat (LTR). The infectious titer of any given virus stock can
thus be determined by staining cultures for β-galactosidase
expression and counting the number of blue cells. Fig. 3 depicts
Fig. 4. Co-receptor preference of ConB Envs. JC53-BL cells were pretreated
with AMD3100 (inhibitor of CXCR4), TAK779 (inhibitor of CCR5), both or
neither (media only) prior to addition of virions containing the Env proteins
indicated. Virus infectivity is plotted on the vertical axis as a percentage of the
untreated control. The CCR5-tropic YU-2 and the CXCR4-tropic NL4.3 Envs
were included as controls.
Fig. 3. Infectivity of virions containing ConB Envs. Virus stocks were generated
by co-transfection of ConB (ConB gp160, ConB gp160-UNC, ConB gp145,
ConB gp160-201N/S) and contemporary (CAAN5342.A2, WITO41260.27)
env genes with HIV-1/SG3Δenv. Infectivity was assessed in JC53-BL cells by
determining the number of blue cells (infectious units, IU) per nanogram of p24.
Bars indicate standard errors (values are averaged from 3 independent
experiments). Infectivity values of virions containing YU-2 and NL4.3 Envs
are shown for control.
222 D.L. Kothe et al. / Virology 360 (2007) 218–234the infectious titer of ConB Env containing pseudovirions
normalized for Gag p24 protein content. Except for the
cleavage-defective gp160-UNC variant (which as expected
was fusion defective), all other ConB glycoproteins conferred
infectivity to HIV-1/SG3Δenv, albeit with varying efficiencies.
In three different experiments, ConB gp160 Env-containing
particles were the most infectious, reaching titers of up to 8078
IU/ng p24. ConB gp145 Env containing pseudovirions were
slightly less infectious, but this difference was not significant
(Fig. 3). However, markedly reduced levels of β-galactosidase
expressing JC53-BL cells were observed for the glycosylation
site mutant of ConB. In three independent experiments, the
relative infectivity of ConB gp160-201N/S Env containing
pseudovirions was approximately 10-fold lower than that of
ConB gp160 containing particles, and this difference was
statistically significant (p<0.0005). The contemporary control
envelopes also varied in their ability to mediate cell entry.
Pseudovirions containing the CAAN5342.A2 Env infected
JC53-BL cells efficiently, exhibiting titers well within the range
of standard laboratory controls, YU-2 and NL4.3. In contrast,
particles containing WITO4160.27 Env were only poorly
infectious (23 IU/ng p24), suggesting a partially impaired
envelope structure and/or function (Fig. 3). Of note, all
consensus and wild-type Envs used CCR5 as the co-receptor
for cell entry (Fig. 4).
Sensitivity of ConB Env glycoproteins to neutralization by
patient plasma
To determine whether native and modified ConB envelope
glycoproteins retained neutralizing epitopes also found incontemporary subtype B viruses, ConB gp160, gp145, and
gp160-201N/S Env containing virions were tested for sensi-
tivity to neutralization by “high reactive” and “low reactive”
plasma pools (derived from HIV-1 infected individuals
previously determined to have high and low titers of
neutralizing antibodies against subtype B viruses, respectively).
As shown in Figs. 5A and B, ConB gp160 and gp145 Envs were
more sensitive to neutralization by patient plasma than YU2
Env, but less sensitive than NL4.3 Env. The neutralization
profile of CAAN5342.A2 Env was comparable to that of YU-2,
while WITO4160.27 Env exhibited greater sensitivity similar to
NL4.3 Env. Interestingly, ConB gp160-201N/S represented the
most sensitive Env, yielding IC50 values of 1:2891 and 1:288 for
the high and low reactive pools, respectively. Thus, a single
amino acid substitution and associated glycosylation site
change at the base of the V1V2 loop resulted in a greater than
5-fold increase in neutralization sensitivity of ConB Env to
pooled patient plasma.
To follow-up on these results, the same panel of ConB and
wild-type Envs was tested for neutralization by plasma samples
from seven individuals chronically infected with HIV-1 subtype
B. As shown in Fig. 6, ConB gp160 and gp145 Envs were
equally sensitive to neutralization by patient plasma, with IC50
titers of up to 1:700 for ConB gp160 and 1:500 for ConB gp145.
CAAN5342.A2 Env was similar to YU2 Env (median titers
were 7 and 15, respectively), while WITO4160.27 Env was
similar to NL4.3 Env (median titers were 209 and 296,
respectively). Again, the most sensitive Env was the glycosyla-
tion site mutant ConB gp160-201N/S, exhibiting IC50 titers of
1:402 to 1:7485. Thus, both ConB gp160 and gp145 envelope
glycoproteins retained neutralizing epitopes common to con-
temporary (primary) subtype B viruses. Moreover, an Env
Fig. 6. Neutralization of ConB Env containing virions by patient plasma. Plasma
samples from seven subtype B infected individuals were tested for their ability to
neutralize ConB or contemporary Env containing virions. Neutralization was
scored as the plasma dilution required to reduce virus infectivity by 50% (IC50).
Vertical boxes represent the 25th and 75th percentiles of the IC50 values, the line
in the box the median, and the lines emerging from the box the highest and
lowest serum dilutions observed for the group, respectively.
Fig. 7. Neutralization of ConB Env containing virions by soluble CD4.
Neutralization of viral infectivity in JC53-BL cells (y-axis) was scored as the
concentration of sCD4 (x-axis) required to reduce virus infectivity by 50%
(IC50) (grey line).
Fig. 5. Neutralization of ConB Env containing virions by “high reactive” (A)
and “low reactive” (B) plasma pools. Neutralization of viral infectivity in JC53-
BL cells (y-axis) was scored as the plasma dilution (x-axis) required to reduce
virus infectivity by 50% (IC50) (grey line).
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increased the sensitivity of the ConB gp160 to neutralization by
both pooled and individual patient plasma by up to 12-fold.
Sensitivity of ConB Env glycoproteins to neutralization by
soluble CD4 and monoclonal antibodies
Primary isolates of HIV-1 display varying degrees of
sensitivity to neutralization by soluble CD4 (sCD4) and
monoclonal antibodies (e.g., IgG1b12, 2G12, 2F5, and 4E10)
(Binley et al., 2004; Li et al., 2005). We thus tested the
sensitivity of the ConB Env proteins to neutralization by these
same reagents. As shown in Fig. 7, ConB gp160, ConB
gp145, and CAAN5342.A2 Envs were completely resistant to
neutralization by sCD4 when assayed at a maximum
concentration of 100 nM. ConB gp160-201N/S Env was
significantly more sensitive, yielding an IC50 value of 54 nM.
Finally, NL4.3, YU2, and WITO4160.27 Envs were most
sensitive, yielding IC50 values of 1.7 nM, 9.2 nM, and 9.5 nM,
respectively.The monoclonal antibody IgG1b12 recognizes a neutraliz-
ing epitope on gp120 that overlaps the CD4-binding site
(Pantophlet and Burton, 2006). As shown in Fig. 8A, all
envelopes tested were sensitive to neutralization by IgG1b12,
except ConB gp160-201N/S and CAAN5342.A2. ConB
gp160 and WITO4160.27 Envs yielded IC50 values of
0.6 μg/ml; ConB gp145 Env was about 4-fold more
sensitive, yielding an IC50 of 0.16 μg/ml. As reported
previously (Wei et al., 2003), YU2 Env was quite resistant
(IC50 2.5 μg/ml), while NL4.3 was highly sensitive (IC50
0.03 μg/ml). Thus, in the context of the ConB envelope
glycoprotein, truncation of the gp41 cytoplasmic domain
caused a conformational change in gp120 that resulted in
Fig. 8. Neutralization of ConB Env containing virions by monoclonal antibodies. Neutralization of viral infectivity in JC53-BL cells (y-axis) by monoclonal antibodies
IgGb12 (A), 2G12 (B), 2F5 (C), 4E10 (D), 17b (E) and E51 (F) was scored as the antibody concentration (μg/ml; x-axis) required to reduce virus infectivity by 50%
(IC50) (grey line).
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asparagine to serine substitution at position 201 in gp120 had
the opposite effect.The various ConB and control Envs were also tested for
neutralization by the monoclonal antibody 2G12 (Fig. 8B)
which recognizes clustered mannose residues on the silent face
Fig. 9. Humoral immune responses to DNA vaccination. Guinea pigs were
vaccinated three times at 4-week intervals with plasmid DNA containing ConB
(ConB gp160, ConB gp160-UNC, ConB gp145, ConB gp160-201N/S) or
contemporary env genes (CAAN5342.A2-opt, WITO4160.27-opt). Two-weeks
following the third vaccination, sera were assayed for the presence of binding
antibodies to their respective (cognate) gp120 proteins. Sera were serially
diluted and the last dilution giving absorbance values greater than twice the
optical density (OD) value of the negative control was identified as the endpoint
titer. Vertical boxes indicate the mean endpoint titer±SEM for each of the
groups indicated.
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Burton, 2006). CAAN5342.A2 and YU-2 Envs were completely
resistant to neutralization by 2G12 (IC50 values >10 μg/ml),
while WITO4160.27 and NL4.3 Envs were somewhat sensitive
(IC50 values 1.3 μg/ml and 1.0 μg/ml, respectively). The three
ConB Envs were most sensitive, with very similar IC50 values
ranging from 0.2 μg/ml to 0.3 μg/ml. Thus, the 2G12 epitope is
present on the consensus subtype B envelope glycoprotein and
not influenced by the Env modifications present in ConB gp145
and ConB gp160-201N/S.
The monoclonal antibodies 2F5 and 4E10 recognize
epitopes in the membrane proximal external region (MPER),
and 4E10 has broad neutralizing activity (Binley et al., 2004).
CAAN5342.A2 and YU-2 Envs were resistant to neutralization
by both 2F5 and 4E10, while WITO4160.27 and NL4.3 Envs
were relatively more sensitive (Figs. 8C and D). ConB gp160
was quite resistant (5.2 μg/ml and 3.7 μg/ml for 2F5 and 4E10,
respectively); ConB gp160-201N/S was more sensitive
(1.1 μg/ml and 0.9 μg/ml); however, surprisingly, ConB
gp145 Env was by far the most sensitive envelope, yielding
IC50 values of 0.18 μg/ml and 0.27 μg/ml for 2F5 and 4E10,
respectively. Since the 2F5 and 4E10 epitopes were not altered in
ConB gp145, it seems clear that truncation of the gp41 cyto-
plasmic domain facilitates greater accessibility of the MPER
region, at least within the context of the ConB Env protein.
Finally, to determine whether removal of an N-linked
glycosylation site at position 201 in the ConB Env resulted in
increased exposure of the CCR5-binding site, we performed
neutralization assays using the co-receptor binding site
antibodies, 17b and E51 (Wyatt et al., 1995; Trkola et al.,
1996a; Sullivan et al., 1998; Wyatt et al., 1998; Kwong et al.,
1998; Xiang et al., 2003). As expected, in the absence of sCD4,
neither antibody was able to neutralize ConB gp160, ConB
gp145, CAAN5342.A2, or YU2 Envs (Figs. 8E and F); however,
ConB gp160-201N/S Env reached IC50 values of approximately
10 μg/ml for both antibodies, suggesting increased formation
and/or exposure of the coreceptor binding site in this particular
mutant. Of note, the poorly infectious WITO4160.27 Env was
also relatively more sensitive to neutralization by 17b and E51
(6.0 μg/ml and 2.0 μg/ml, respectively), as was the control
NL4.3 Env as previously described (Wei et al., 2003).
Humoral immune responses to ConB Envs in DNA immunized
guinea pigs
To explore the immunogenicity of synthetic subtype B env
constructs in vivo, guinea pigs (six or twelve animals per group)
were immunized three times at 4-week intervals with 400 μg of
ConB gp160, ConB gp160-UNC, ConB gp145, and ConB
gp160-201N/S env DNA, as well as 400 μg of CAAN5342.A2-
opt and WITO4160.27-opt env DNA for wild-type control. Two
weeks following the second and third immunization, serum
samples were collected from each animal and assayed for the
presence of binding antibodies to the respective (cognate)
gp120 glycoprotein using an ELISA assay. As shown in Fig. 9,
all ConB DNAvaccines elicited binding antibodies that reached
endpoint titers of up to 1:160,000 after the third immunization.Surprisingly, the binding antibody titers of guinea pigs vacci-
nated with the two contemporary env genes, WITO4160.27-opt
and CAAN5342.A2-opt, were 10 to 40-fold lower. This was not
due to type specific immune responses since the cognate gp120
proteins were used for their detection. Moreover, the lower
binding antibody titers did not reflect an overall reduced
immunogenicity, since CAAN5342.A2 env was as potent as
ConB gp160 with respect to inducing neutralizing antibodies
(see below).
Sera from immunized guinea pigs were next tested for
neutralizing antibodies using a single-round infectivity assay
as described (Wei et al., 2003; Decker et al., 2005; Li et al.,
2005). Each serum was analyzed at a 1:10 dilution and its
neutralization activity determined relative to the baseline
activity of the pre-immune serum from the same animal. In
addition, each pre- and post-immunization serum was tested
for neutralization of MuLV envelope-containing virions. Thus,
all neutralization values generated were quality controlled not
only for non-specific anti-viral but also anti-cellular serum
activities (Table 1). We developed this approach specifically
for DNA vaccination studies because of the expected low
titer neutralizing responses. We reasoned that after correction
of non-specific serum activity both at the pre- and post
immune level, even a modest reduction of infectivity at a
1:10 serum dilution would indicate HIV-1 Env specific neutra-
lization. Using this approach, we were thus able to conduct
meaningful comparisons even of very low level neutralization
responses.
Table 1
Neutralizing activity of sera from DNA immunized guinea pigsa
aNeutralization of a panel of ConB andwild-type Env containing viruses by sera from guinea pigs immunized with the DNAvaccines indicated (see first column). Numbers
in the table indicate the percent of HIV-1 Env specific neutralization at a 1:10 serum dilution (see Materials and methods). Values are from single experiments performed in
duplicate. Negative neutralization values are reported as “0”. Light and dark blue boxes indicate 1–50% and ≥50% neutralization, respectively. bPseudovirions were
generated using wild-type (not codon optimized) env clones of CAAN5342.A2 gp160 and WITO4160.27 gp160. cViruses tested only once due to limited serum volume.
226 D.L. Kothe et al. / Virology 360 (2007) 218–234Table 1 summarizes the results of the neutralization
studies. All guinea pigs except one (animal 229) developed
antibodies that neutralized at least one of the viruses listed,albeit at very low levels. The viruses most commonly
neutralized were those containing globally sensitive envel-
opes, including WITO4160.27 and ConB gp160-201N/S (also
227D.L. Kothe et al. / Virology 360 (2007) 218–234see Fig. 6), as well as the tier 1 viruses, SS1196.1 and SF162
(Mascola et al., 2005; Li et al., 2005). Interestingly, 81% of
guinea pig sera also had neutralizing activity against the
relative more resistant CAAN5342.A2 Env. However, less
than half of the immunized animals developed a neutralizing
antibody response against tier 2 viruses 3988.25, SC422661.8,
THRO4156.18, and REJO4541.67 which represent relative
resistant (subtype matched) primary isolates (Li et al., 2005).
Importantly, there were no significant differences between
autologous and heterologous responses for any of the immuno-
gens tested, indicating that immunizationwith ConB env vaccines
did not confer significantly greater neutralizing power against
consensus B glycoproteins.
We next asked whether statistically significant differences
existed between consensus and wild-type immunogens with
respect to breadth and magnitude of the elicited response. In a
first step, we combined heterologous neutralization data for
the four ConB and the two wild-type env immunogens, and
compared these as two different groups. Using a Wilcoxon
rank sum test with continuity correction, we found no
significant differences in the breadth of the neutralizing
antibody response, i.e., antibodies from both immunogen
groups neutralized a similar number of viruses (p=0.1482);
however, compared to the contemporary immunogens, ConB
env vaccines elicited an antibody response of greater
magnitude (p=0.0121), as reflected by the number of sera
that reduced virus infectivity by 50% or more (highlighted in
dark blue in Table 1).
In a second step, we wished to compare individual immu-
nogens with respect to their relative potency (defined as a
combination of both breadth and magnitude). For this analysis,
all neutralization data listed Table 1 were subjected to multiple
pairwise comparisons using Tukey's Honestly Significant
Difference procedure as described in Materials and methods.Fig. 10. Relative potency of ConB and wild-type env vaccines as determined by com
viruses (B), and tier 2 viruses (C), as indicated in Table 1. Neutralization data we
Significant Difference procedure). An estimated difference between neutralization co
(brackets) is shown for all pairwise comparisons of immunogens (as indicated on the
that the first named immunogen of the pair was better at eliciting a neutralizing antibod
with 95% confidence intervals that do not cross the dotted vertical line indicate statFig. 10 depicts the estimated differences between neutralization
coefficients (solid circles) determined for all possible combina-
tions of immunogens, as well as a 95% confidence interval for
those differences (brackets). A negative difference (circle to the
left of the vertical line) indicates that the first named
immunogen in the pair is more potent at eliciting a neutralizing
antibody response than the second named immunogen.
Conversely, a positive difference (circle to the right of the
vertical line) indicates that the first named immunogen in the
pair is less potent than the second named immunogen.
Confidence intervals that do not cross the dotted vertical line
indicate statistically significant differences in potency. When
responses against all 12 viruses listed in Table 1 were included
(Fig. 10A), ConB gp145 env emerged as the best and
WITO4160.27 env as the worst immunogen, with no significant
potency differences observed for the remainder of the immuno-
gens. Analyzing only responses to tier 1 viruses (SF162 and
SS1196.1) yielded similar results (Fig. 10B): ConB gp145 and
ConB gp160 env vaccines, were found to be significantly more
potent than the two wild-type immunogens WITO4160.27 and
CAAN5342.A2. However, restricting the analysis to tier 2
viruses (3988.25, QH0692.42, SC422661.8, THRO4156.18,
REJO4541.67) resulted in the loss of all statistically significant
differences between consensus and wild-type immunogens
(Fig. 10C).
Finally, to test for the presence of CD4i antibodies, guinea
pig sera were incubated with virions containing an HIV-2
envelope glycoprotein (HIV-2/7312A) in the presence and
absence of sCD4 as described (Decker et al., 2005). No
reduction of infectivity was observed indicating the absence of
neutralizing antibodies directed against the CCR5 binding site
(not shown). Guinea pig sera were also tested using virions that
contained a chimeric HIV-2 envelope expressing the entire 23
amino acid HIV-1 MPER region. Such HIV-2 Env scaffoldsparison of neutralization responses against the entire panel of viruses (A), tier 1
re analyzed by performing multiple pairwise comparisons (Tukey's Honestly
efficients (solid circles) as well as a 95% confidence interval for that difference
left). A negative difference (circle to the left of the vertical dotted line) indicates
y response than the second named immunogen. Pairwise comparison differences
istically significant differences in potency.
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lizing antibodies as well as antibodies directed against other
epitopes in the MPER region (Bibollet-Ruche et al., 2006).
Again, no reduction in infectivity was observed, indicating the
absence of MPER neutralizing antibodies in all vaccinated
guinea pigs (not shown).
Discussion
In this study, we characterized the biologic and antigenic
properties of four synthetic HIV-1 subtype B env gene products
and compared their ability to elicit neutralizing antibodies when
used as DNAvaccines in guinea pigs. The purpose of this study
was to address three questions: (i) can consensus subtype B env
genes be generated that encode functional glycoproteins; (ii) is
there an advantage for the use of consensus over contemporary
subtype B env immunogens for eliciting neutralizing antibodies;
and (iii) can consensus glycoproteins be modified to improve
their immunogenicity.
Biologic and antigenic properties ConB envelope glycoproteins
Despite their artificial nature, full-length and truncated
subtype B consensus env genes encode functional glycopro-
teins. Both ConB gp160 and ConB gp145 Envs conferred
infectivity to pseudotyped virions at levels comparable to wild-
type envelope glycoproteins. ConB gp160-UNC was cleavage
defective and thus non-infectious. Finally, the ConB
gp160201N/S mutant was processed and packaged, but
particles containing this envelope were less infectious. Since a
similar phenotype has recently been described for HIV-1 and
SHIV Env proteins with glycosylation site changes at analogous
sites (Kolchinsky et al., 2001a,b; Hu et al., 2005), these data
indicate that consensus subtype B envelopes, like their wild-
type counterparts, can be modified in an overall predictable
fashion.
Truncation of the cytoplasmic domain of gp41 has been
reported to expose otherwise hidden neutralizing epitopes in
wild-type HIV-1 envelopes (Edwards et al., 2002). Although
increased sensitivity to neutralization by certain monoclonal
antibodies was observed (Fig. 8), ConB gp145 did not exhibit
the globally sensitive phenotype of the previously described
cytoplasmic domain truncated HIV-1 envelopes, JRFL and
ADA (Edwards et al., 2002). The latter were highly sensitive to
neutralization by pooled patient sera as well as monoclonal
antibodies directed to the CD4-binding site (IgG1b12) and the
bridging sheet (17b, 48d) (Edwards et al., 2002). ConB gp145
was not particularly sensitive to neutralization by patient plasma
and resistant to CD4i monoclonal antibodies (Figs. 5, 6, and 8).
However, ConB gp145 was 5- to 10-fold more sensitive than
ConB gp160 to neutralization by IgG1b12, 2F5, and 4E10. Of
note, the truncated JRFL and ADA mutants each retained a
cytoplasmic domain of 43 amino acids, while ConB gp145 was
truncated immediately after the membrane spanning domain. It
is thus possible that the only modest increase in neutralization
sensitivity of ConB gp145 Env is due to these length differences
and/or is context dependent. Nonetheless, our results show thatgp41 truncations do alter the presentation of neutralizing
epitopes within the ConB envelope.
Removal of a single N-linked glycosylation site at the base
of the V1V2 loop has been reported to render wild-type HIV-1
envelopes more neutralization sensitive (Kolchinsky et al.,
2001a,b; Hu et al., 2005), and in the case of one envelope
(HIV-1/ADA) to result in a CD4 independent phenotype
(Kolchinsky et al., 2001b). Alteration of an N-linked glycosyla-
tion site at the analogous position in ConB gp160-201N/S also
resulted in an increased sensitivity to neutralization by patient
plasma, sCD4, and monoclonal antibodies recognizing the
MPER region and the bridging sheet (Figs. 5–8). However, this
increase was only modest compared to the corresponding ADA
mutant (197N/K). Moreover, the ConB gp160-201N/S Env
remained CD4 dependent (not shown) and was resistant to
neutralization by IgG1b12. It is believed that the CD4 binding
site of the HIV-1 Env is partially occluded by the V1V2 loop and
that the position of this loop (and thus access to the CD4 binding
site) can be altered by the removal of a carbohydrate at its base
(Kolchinsky et al., 2001a). We found that removal of this
glycosylation site in ConB Env was not sufficient to increase
neutralization by the CD4 binding site antibody IgG1b12
(Fig. 8A). However, introduction of a lysine rather than a serine
at position 201 in ConB Env increased IgG1b12 neutralization
sensitivity by 30-fold (ConB gp160-201N/K; IC50=0.02 μg/ml;
data not shown). Thus, in addition to the glycosylation site, the
particular amino acid at the base of the V1V2 loop (position 201
in ConB and 197 in ADA) appears to represent an important
determinant of IgG1b12 sensitivity, at least in the context of the
ConB envelope.
Immunogenic properties ConB envelope glycoproteins
A major goal of AIDS vaccine development is the induction
of potent and broadly cross-reactive antibodies that neutralize
the majority of currently circulating HIV-1 variants. In this
study, we compared four ConB and two wild-type env
immunogens following DNA immunization of guinea pigs.
Sera were tested against a panel of 12 viruses (Table 1) which
included the vaccine strains as well as subtype matched tier 1
and tier 2 viruses (Mascola et al., 2005; Li et al., 2005).
Neutralizing antibodies were detected in all but one immunized
guinea pig (Table 1), although the magnitude of the response
was overall very low. At a 1:10 dilution, only 30% of all
antibody positive sera reduced viral infectivity by more than
50% and none of these exceeded 85% neutralization. Given that
env DNA vaccines rarely elicit neutralizing antibodies, these
results are not unexpected. In fact, compared to neutralizing
responses induced by wild-type and centralized subtype C env
DNA vaccines, the subtype B responses are considerably more
potent (Kothe et al., 2006).
A key question in current AIDS vaccine development is
whether there is an advantage of using consensus rather than
contemporary env immunogens for eliciting neutralizing
antibodies. The results in Table 1 were rigorously controlled
for both non-specific anti-viral and anti-cellular serum activ-
ities. Thus, it was possible to examine the relative utility of
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comparing only low level antibody responses. Conducting
multiple pairwise comparisons, we found that ConB env DNA
vaccines were at least as potent as wild-type subtype B env
DNA vaccines (Fig. 10). Thus, there certainly was no
disadvantage associated with using consensus env vaccines.
Moreover, depending on the viruses selected for analysis, ConB
gp145 and to a lesser extent ConB gp160 were significantly
more potent than either wild-type env vaccine (Figs. 10A and
B). Between the two wild-type controls, the neutralization
resistant CAAN5342.A2 env elicited a significantly more
potent neutralizing antibody response than the globally
neutralization sensitive WITO4160.27 env (Fig. 10A). When
analyses were restricted to tier 1 or tier 2 viruses, most of the
significant relationships were lost (Figs. 10B and C); however,
in these instances, WITO4160.27 env still tended to rank at the
bottom of all immunogens. These results highlight the difficulty
of randomly selecting a contemporary envelope as a suitable
vaccine candidate.
Numerous env modifications including the removal of N-
linked glycosylation sites, deletion of variable loops, and
cytoplasmic tail truncations have been tested for their ability to
improve the neutralizing antibody response to HIV-1 env
vaccines (Barnett et al., 2001; Hu et al., 2005; Kim et al.,
2005; Liao et al., 2006; Quinones-Kochs et al., 2002).
Collectively, these studies have shown that improvements are
possible, but that successful modifications are frequently strain
and/or context dependent (Barnett et al., 2001; Chakrabarti et
al., 2002). We found that in the context of the ConB envelope,
truncation of the cytoplasmic domain of gp41 was the most
effective means to improve immunogenicity. ConB gp145 was
significantly more potent than all other immunogens when
tested against the entire virus panel (Fig. 10A) and remained
the best immunogen when only tier 1 virus responses were
analyzed (Fig. 10B). Even when analyses were restricted to
tier 2 virus responses, ConB gp145 still ranked among the
most potent immunogens, although this was no longer
statistically significant (Fig. 10C). Interestingly, a recent
study of patients with unusually broad neutralizing antibody
responses revealed that these individuals harbor viruses whose
envelopes have increased sensitivity to neutralization by 2F5
and 4E10 (Cham et al., 2006). ConB gp145 was also markedly
more sensitive to neutralization by 2F5 and 4E10 (Fig. 8); yet,
it did not elicit detectable MPER antibodies in guinea pigs.
Thus, both in the patients with broadly cross-reactive
neutralizing antibodies (Cham et al., 2006) and in the ConB
gp145 immunized guinea pigs, the enhanced 4E10 and 2F5
sensitivity may be a surrogate of increased exposure of other
neutralizing epitopes. Additional studies will be necessary to
test this hypothesis.
ConB gp160-201N/S was constructed with the expectation
that the asparagine to serine change at position 201 would
increase antibody access to conserved epitopes normally
occluded by the V1V2 loop. Although the sensitivity of ConB
gp160-201N/S to neutralization by patient sera was markedly
enhanced, the removal of the glycosylation site did not generate
a superior immunogen. ConB gp160-201N/S elicited a neu-tralizing antibody response comparable to ConB gp160 and
ConB gp160-UNC, but not as good as ConB gp145 (Fig. 10).
Interestingly, a glycosylation change at the analogous site in a
vaccinia based 89.6 Env immunogen induced neutralizing
antibodies in macaques that were protective against an 89.6
Env containing SHIV challenge (Hu et al., 2005). These
findings reemphasize the context dependent nature of Env
modifications. Finally, the uncleaved version of ConB gp160
was not improved relative to cleaved ConB gp160 version as
an immunogen.
Conclusions
In summary, we report here that consensus subtype B env
genes express glycoproteins that resemble wild-type Envs in
their overall structure and function, and that they elicit low
level neutralizing antibody responses when administered as
DNA to guinea pigs. Comparisons of individual immunogens
indicate that ConB env vaccines are at least as potent, and in
some instances more potent than wild-type env vaccines.
Moreover, like their wild-type counterparts, consensus env
immunogens are amenable to improvement by specific gene
modifications. Given their documented utility for eliciting
broadly cross-reactive T cell responses, consensus envelope
immunogens should continue to be evaluated as potential
components of future AIDS vaccines. In this context, it will be
important to establish the relative merits of vaccines designed
to be central to the entire M group versus those that are central
to a single clade.
Materials and methods
Gene synthesis
The HIV-1 subtype B consensus full-length env gene
sequence was codon-usage optimized as described (Haas et
al., 1996; Andre et al., 1998; Gao et al., 2003; Kothe et al.,
2006) and is available at Genbank under accession number
DQ667594. All ConB env gene modifications were generated
using the QuikChange Site-Directed Mutagenesis Kit (Invitro-
gen, Carlsbad, CA). The ConB gp160-UNC mutant was made
by altering the primary cleavage site REKR to SEKS. ConB
gp145 was generated by introduction of a premature stop codon
(TAA) that truncates the envelope glycoprotein immediately
after the membrane spanning domain. Lastly, ConB gp160-
201N/S was generated by removing a potential N-linked
glycosylation site at position 201 (201N/S). Individual env
variants were sequence confirmed and cloned into pcDNA3.1
(Invitrogen, Carlsbad, CA).
Contemporary subtype B env genes were cloned by reverse
transcriptase polymerase chain reaction (RT-PCR) amplifica-
tion from the plasma of individuals with acute (WITO4160)
and early (CAAN5342) HIV-1 infection (Li et al., 2005).
CAAN5342 clone A2 has been characterized extensively
and represents one of twelve subtype B env clones (SVPB19)
included in a standard virus panel to assess neutralizing antibody
responses (Li et al., 2005); WITO4160 clone 27 has not
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plasma sample as WITO4160 clone 33, also included in the
standard subtype B env panel (SVPB18) (Li et al., 2005).
The nucleotide sequences of the codon-usage optimized
CAAN5342.A2 and WITO4160.27 env genes are available
under accession numbers DQ821487 and DQ667595 (the corre-
sponding wild-type sequences are available under AY835452
and DQ824742, respectively).
Western blot analysis of pseudovirion stocks
To test whether full-length and modified subtype B con-
sensus Envs were capable of incorporating into virus particles,
each gene was transfected with an env-minus HIV-1 backbone
vector (SG3Δenv). Transfections were performed in 100 mm-
diameter dishes containing a 60% confluent layer of 293T cells
in complete Dulbecco's Modified Eagle Media (DMEM) using
FuGene 6 (Roche Applied Science, Indianapolis, IN) as
specified by the manufacturer. Forty-eight hours post-transfec-
tion, virus-containing supernatants were collected, clarified by
low-speed centrifugation, passed through a 0.2 μm filter, and
pelleted through a 20% sucrose cushion. Pelleted virus was
normalized for p24 Gag content and then subjected to SDS-
PAGE and Western blot analysis. Blots were probed with
antibodies specific for HIV-1 Env glycoproteins (USB 6001-15,
US Biologicals, Swampscott, MA) and p24 Gag (AG3.0, NIH
AIDS Research & Reference Reagent Program, Bethesda, MD)
and developed using HRP-labeled antibodies (SouthernBiotech,
Birmingham, AL) and an enhanced chemiluminescence (ECL)
based detection system (GE Healthcare Life Sciences, Piscat-
away, NJ).
Infectivity and co-receptor usage of ConB Env containing
pseudovirions
Infectivity assays were performed as described (Derdeyn et
al., 2000). Briefly, JC53-BL cells were seeded in 24-well plates
at 50,000 cells per well in DMEM supplemented with 10% fetal
bovine serum, and incubated overnight. Pseudotyped virus
stocks containing ConB gp160, ConB gp160-UNC, ConB
gp145, or ConB gp160-201NS Envs were added to each well in
the presence of DEAE-Dextran hydrochloride (80 μg/ml)
(Sigma-Aldrich, St. Louis, MO) in a final volume of 250 μl.
Following a 48-h incubation, plates were washed, stained, and
the number of blue cells counted to determine the infectious
virus titer.
A modification of the infectivity assay was used to determine
the co-receptor usage of the various consensus envelopes using
antagonists to CXCR4 (AMD3100) and CCR5 (TAK-779)
(Zhang et al., 2000; Spenlehauer et al., 2001). Briefly, JC53-BL
cells were seeded overnight and then treated for 1 h with
AMD3100 (1.2 μM/well), TAK-779 (10 μM/well), a combina-
tion of these chemokine receptor blocking agents, or media.
2000 infectious units of pseudotyped virions were added to each
well in the presence of 80 μg/ml DEAE-Dextran hydrochloride
and incubated at 37 °C. Following a 2-day incubation,
supernatant was removed, and cells were lysed using aluciferase assay system kit (Promega, Madison, WI). The
light intensity of each cell lysate was measured on a Tropix
luminometer using Tropix WinGlow version 1.24 software. A
reduction in infectivity in the presence of a specific inhibitor
reflects a requirement of the targeted co-receptor for entry.
Neutralization sensitivity of ConB Env containing virions to
patient plasma and neutralizing monoclonal antibodies
Pseudovirions containing the ConB gp160, ConB gp145,
ConB gp160-201N/S, CAAN5342.A2, or WITO4160.27
envelope glycoproteins were examined for sensitivity to neu-
tralization by patient plasma and monoclonal antibodies using a
single round infectivity assay. Pseudovirions containing the
standard laboratory Envs, YU-2 and NL4.3, were included as
controls. JC53-BL cells were seeded at 8000 cells per well in a
96-well plate in 10% DMEMmedia overnight at 37 °C with 5%
CO2. Plasma from HIV-1 subtype B infected individuals were
serially diluted and incubated with 2000 units of infectious virus
per well for 1 h at 37 °C. Pre-incubated virus/plasma dilutions
were added to the cells in the presence of DEAE-Dextran and
incubated for 2 days at 37 °C. Control wells containing
pseudovirions that had not been pre-incubated with antibody
were included for each virus tested. Additionally, cell-only
wells were included on each plate as a measure of background.
Cells were lysed and analyzed for luciferase activity by
measuring relative light units (RLU) in a Tropix luminometer
using Tropix WinGlow version 1.24 software. Neutralization
was measured as the percent reduction of viral infectivity in
comparison to control wells infected with virus alone. A similar
assay was used to assess pseudovirion sensitivity to neutraliza-
tion by soluble CD4 (sCD4) (R&D Systems, Minneapolis, MN)
and a panel of human monoclonal antibodies. The following
monoclonal antibodies were obtained through the AIDS
Research and Reference Reagent Program, National Institute
of Allergy and Infectious Diseases, National Institutes of
Health: IgG1b12 (Roben et al., 1994), 2G12 (Trkola et al.,
1996b), 2F5 (Muster et al., 1993), 4E10 (Buchacher et al.,
1994), and 17b (Sullivan et al., 1998). The E51 monoclonal
antibody was obtained from J. Robinson (Tulane University
School of Medicine, New Orleans, LA). For these assays,
infectious virus (2000 IU) was pre-incubated with serial
dilutions of sCD4 (using concentration ranging from
0.0001 μM to 100 μM) and monoclonal antibodies (using
concentration ranging from 0.0001 μg/ml to 10 μg/ml) and then
added to JC53-BL cells.
Guinea pig immunization and serum collection
Guinea pigs were housed according to Accreditation of
Laboratory Animal Care (AALAC) guidelines. All protocols
were approved by the Institutional Animal Care and Use
Committee. Female Hartley guinea pigs (Harlan Sprague,
Indianapolis, IN) (n=12/group for ConB gp160 and ConB
gp160-201N/S DNA vaccines; n=6/group for ConB gp160-
UNC, ConB gp145, CAAN5342.A2-opt, and WITO4160.27-
opt DNA vaccines) were immunized intramuscularly three
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weeks following the last immunization, 5 ml of blood was
collected from each animal via the cranial vena cava. Sera were
obtained by tabletop centrifugation using Becton Dickinson
SST Tubes (BD, Franklin Lakes, NJ). Samples were stored at
−20 °C until analysis.
Endpoint binding titer ELISA for anti-Env antibody detection
in immunized guinea pigs
Guinea pig sera were tested for binding antibodies to their
cognate gp120 protein in an enzyme linked immunosorbent
assay (ELISA). ConB, CAAN5342.A2, and WITO4160.27
gp120 glycoproteins were produced by transfecting 293T cells
with the corresponding plasmids (engineered to contain a
premature stop codon immediately prior to the gp160
cleavage site). Supernatants were harvested 72 h post-
transfection, clarified by centrifugation, and passed through
a 0.2 μM filter. Recombinant gp120 was purified using
Galanthus Nivalis Lectin (GNL) (Vector Laboratories, Bur-
lingame, CA), eluted with 500 mM alpha-methyl mannoside
(Vector Laboratories, Burlingame, CA), dialyzed overnight in
PBS, and quantified using a BCA Protein Assay (Pierce
Biotechnology, Rockford, IL). Microtiter plates were coated
with recombinant gp120 (0.5 μg/ml in PBS), washed and
blocked with 200 μl per well 5% nonfat milk in PBS-T. Serial
five-fold dilutions were made of each guinea pig serum,
added to individual wells, and set to incubate for 1 h at
37 °C. Following a wash, 100 μl of HRP-conjugated goat
anti-guinea pig antibody (ICN Pharmaceuticals, Costa Mesa,
CA), diluted to 1:50,000 in blocking buffer was added to each
well. After an additional 1-h incubation at 37 °C, 100 μl of
liquid TMB (3,3′,5,5′-tetramethylbenzidine) was added to
each well. Reactions were stopped by the addition of 100 μl
of 4 N sulfuric acid. Absorbances were read at 405 nm on an
MRX Microplate reader (DYNEX Technologies, West
Sussex, UK). Endpoint titers were determined as the serum
titer at which the absorbance value was 2× the mean OD of
the negative serum control.
Neutralization analysis of sera from immunized guinea pigs
Sera from immunized guinea pigs were tested for neutraliz-
ing antibodies in duplicate. Pre- and post-immunization sera
from the same animal were diluted 1:10, incubated with
100,000 relative light units (RLUs) of pseudovirions containing
autologous or heterologous envelope glycoproteins in a total
volume of 150 μl, and added to JC53-BL cells on a 96-well
plate. To control for non-specific antiviral activity, these same
sera were also tested for neutralization of viruses containing the
amphotropic MuLV Env. Background RLUs were measured in
wells containing only JC53-BL cells and media. Following a
48-h incubation of cells and serum dilutions, cells were lysed
and the corresponding RLUs measured using a Wallac 1420
luminometer (Perkin Elmer, Boston, MA) using Wallac 1420
version 3.00 software. Percent neutralization (as shown in Table
1) was calculated for each serum using the following equation(“ENV” represents autologous or heterologous HIV-1 Env
glycoproteins):
1−
ð post−immune RLUENVÞ−ð background RLUENVÞ
ð pre−immune RLUENVÞ−ð background RLUENVÞ
h i
ð post−immune RLUMuLVÞ−ð background RLUMuLVÞ
ð pre−immune RLUMuLVÞ−ð background RLUMuLVÞ
h i
2
4
3
5
2
4
3
5*100
Statistical analyses
To determine the relative potency of each immunogen,
detailed statistical modeling of the respective neutralization
data was undertaken. A survey of the raw neutralization
results suggested that they were log-normally distributed
(Shapiro-Wilk test on all available data, p>0.5; also
supported by separate Shapiro-Wilk tests on each microtiter
plate). Thus, log-transformed neutralization ratios were used
in all subsequent statistical analyses. All statistical modeling
was performed with the statistical package R (R Develop-
ment Core Team, 2006). Models were developed that
predicted the log of the specific neutralization ratio: that
is, the ratio of pre- and post-immune HIV-1 Env specific
neutralization divided by the ratio of pre- and post-immune
MuLV Env specific neutralization. Using a weighted least-
squares approach to account for variations in the pattern of
data replication, models were fit (Crawley, 2002) that
predicted the log specific neutralization ratio as a function
of the immunogen and the target strain. There were no
significant interactions between these parameters (so, for
example, immunization with a specific env vaccine did not
confer significantly greater neutralizing power against that
envelope). To account for multiple testing, a recent
implementation of Tukey's Honestly Significant Difference
procedure (Bretz et al., 2001; Westfall, 1997) was applied,
yielding the simultaneous 95% confidence intervals plotted
in Fig. 10. This procedure is appropriate for experimental
designs that are statistically unbalanced such as the one
described here.
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